Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of Palmar hyperhidrosis

Dermatologic Surgery

Volumn 31, Issue 3, 2005, Pages 263-270

  Baumann, Leslie ^a,b   Slezinger, Anele ^a   Halem, Monica ^a   Vujevich, Justin ^a   Mallin, Karin ^a   Charles, Carlos ^a   Martin, Lucy K ^a   Black, Laura ^a   Bryde, Joy ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN B; PLACEBO; BOTULINUM TOXIN; METALLOPROTEINASE;

ACNE; ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRY EYE; DRY THROAT; ETHNOLOGY; FEMALE; FLU LIKE SYNDROME; GENDER; GRIP STRENGTH; HEARTBURN; HUMAN; HYPERHIDROSIS; INDIGESTION; MALE; MUSCLE WEAKNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SWEATING; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; XEROSIS; XEROSTOMIA; AGED; MIDDLE AGED; PILOT STUDY; QUALITY OF LIFE;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXINS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERHIDROSIS; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE;

EID: 18244372707     PISSN: 10760512     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042728-200503000-00002     Document Type: Article

References (20)

1. Heckmann M, Breit S. Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis. J Am Acad Dermatol 1999;41:987-90.
2. Gossot D, Kabiri H, Caliandro R, et al. Early complications of thoracic endoscopie sympathectomy: a prospective study of 940 procedures. Ann Thorac Surg. 2001;71:1116-9.
3. Lai TY. Complications in patients with palmar hyperhidrosis treated with transthoracic endoscopic sympathectomy. Neurosurgery 1997;41:110-3.
4. Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 1998;38:227-9.
5. Solomon BA, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 2000;42:1026-9.
6. Saadia D, Voustianiouk A, Wang AK, Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology 2001;57:2095-9.
7. Lowe NJ, Yamauchi PS, Lask GP, et al. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 2002;28:822-7.
8. Schweiz BA. First drug for cervical dystonia. JAMA 2001;285:724.
9. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 1999;53:1431-8.
10. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology 1999;53:1439-46.
11. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997;49:701-7.
12. Stolman LP. Treatment of hyperhidrosis. Dermatol Clin 1998;16:863-7.
13. American Academy of Neurology 53rd Annual Meeting, May 5-11, 2001, Philadelphia, Pennsylvania, USA, abstracts. Neurology 2001;56(8 Suppl 3):A1-559.
14. Naumann M, Hofmann U, Bergmann I, et al. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998;134:301-4.
15. Baumann L, Slezinger A, Black L, et al. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of MYOBLOC™ (botulinum toxin type B) in the treatment of axillary hyperhidrosis. Int J Dermatol [In press]
16. Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003;49:34-8.
17. Lowe NJ, Yamauchi PS, Lask GP, et al. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002;4(1):15-8.
18. Sadick NS. Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. Dermatol Surg 2002;28:817-21.
19. Sadick NS. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles. Dermatol Surg 2003;29:501-7; discussion 507.
20. Hund M, Kinkelin I, Naumann M, Hamm H. Definition of axillary hyperhidrosis by gravimetric assessment. Arch Dermatol 2002;138:539-41.